Robeco Institutional Asset Management B.V. Grows Position in Alkermes plc $ALKS

Robeco Institutional Asset Management B.V. increased its holdings in Alkermes plc (NASDAQ:ALKS) by 112.6% in the fourth quarter, Holdings Channel reports. The fund owned 285,670 shares of the company’s stock after purchasing an additional 151,283 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Alkermes were worth $7,993,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ALKS. Baker BROS. Advisors LP lifted its stake in Alkermes by 26.2% in the third quarter. Baker BROS. Advisors LP now owns 8,091,351 shares of the company’s stock worth $242,741,000 after acquiring an additional 1,680,748 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Alkermes by 1,070.6% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,208,944 shares of the company’s stock worth $36,268,000 after acquiring an additional 1,105,666 shares during the period. BNP Paribas Financial Markets raised its holdings in Alkermes by 787.2% in the second quarter. BNP Paribas Financial Markets now owns 1,135,478 shares of the company’s stock worth $32,486,000 after purchasing an additional 1,007,488 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Alkermes in the third quarter worth about $27,040,000. Finally, American Century Companies Inc. raised its holdings in Alkermes by 20.2% in the third quarter. American Century Companies Inc. now owns 4,397,471 shares of the company’s stock worth $131,924,000 after purchasing an additional 740,248 shares in the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Alkermes Trading Down 1.9%

Shares of NASDAQ:ALKS opened at $33.22 on Thursday. Alkermes plc has a twelve month low of $25.17 and a twelve month high of $36.48. The company’s 50 day moving average is $31.39 and its 200 day moving average is $30.73. The company has a market cap of $5.52 billion, a PE ratio of 23.23 and a beta of 0.44.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Saturday, February 14th. The company reported $0.29 earnings per share for the quarter. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The company had revenue of $384.55 million for the quarter. Equities research analysts predict that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Alkermes

In related news, SVP Christian Todd Nichols sold 6,000 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $30.00, for a total value of $180,000.00. Following the transaction, the senior vice president owned 109,769 shares in the company, valued at approximately $3,293,070. This represents a 5.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Shane Cooke sold 61,200 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the completion of the transaction, the director owned 103,744 shares in the company, valued at approximately $3,586,430.08. This trade represents a 37.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 159,468 shares of company stock worth $5,433,699 in the last 90 days. Corporate insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on ALKS shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Alkermes in a report on Monday, December 29th. Wells Fargo & Company boosted their target price on shares of Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Royal Bank Of Canada reduced their target price on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Zacks Research downgraded shares of Alkermes from a “hold” rating to a “strong sell” rating in a report on Friday, March 20th. Finally, Bank of America boosted their target price on shares of Alkermes from $34.00 to $36.00 and gave the stock a “neutral” rating in a report on Thursday, April 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.07.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.